[New Group · Theme Sentiment Batch Post]
The cross-border expansion of innovative drugs has not been quiet this year. Looking at $INNOVENT BIO(01801.HK), $Legend Biotech(LEGN.US), and $Replimune(REPL.US) together, the License-out story continues to roll forward.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments